Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | GUCY1A1 | Q02108 | 10/20 | 0.51 |
| ▸ | GUCY1B1 | Q02153 | 10/20 | 0.51 |
| ▸ | PDE5A | O76074 | 8/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29382996 | 1.00 | ADORA3 (0.60) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL15087585 | 0.94 | ADORA3 (0.58) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL10252555 | 0.91 | ADORA3 (0.62) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL174847 | 0.86 | ADORA3 (0.67) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL23162011 | 0.86 | ADORA3 (0.43) | ADORA3KCNH2GUCY1A1GUCY1B1 | |
| Hydrochloric Acid SCHEMBL1930775 | 0.85 | ADORA3 (0.66) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Hydrochloric Acid SCHEMBL18496411 | 0.85 | ADORA3 (0.66) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL255832 | 0.85 | ADORA3 (0.57) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL458874 | 0.84 | ADORA3 (0.57) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL2365288 | 0.84 | PDE5A (0.50) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 402 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387391-A1 | A SOLUBLE GUANYLAT CYCLASE ACTIVATOR FOR TREATING CHRONIC VASCULAR DYSFUNCTION | UNIV BERLIN CHARITE (DE) | 2025-12-25 | — | — | US | claimed |
| US-20250281485-A1 | DIAGNOSIS AND/OR TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION | UNIVERSITEIT MAASTRICHT (NL) | 2025-09-11 | — | — | US | claimed |
| EP-4511017-A1 | DIAGNOSIS AND/OR TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION | Universiteit Maastricht (NL) | 2025-02-26 | — | — | EP | claimed |
| CN-119367341-A | Methods of treating PAH using RALINEPAG in combination with other agents | 阿瑞那制药公司 | 2025-01-28 | — | — | CN | claimed |
| EP-4472620-A1 | A SOLUBLE GUANYLAT CYCLASE ACTIVATOR FOR TREATING CHRONIC VASCULAR DYSFUNCTION | Charité - Universitätsmedizin Berlin (DE) | 2024-12-11 | — | — | EP | claimed |
| WO-2023204698-A1 | DIAGNOSIS AND/OR TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION | UNIVERSITEIT MAASTRICHT (NL) | 2023-10-26 | — | — | WO | claimed |
| CN-116726178-A | Use of sGC stimulators in the treatment of non-alcoholic steatohepatitis (NASH) | 赛克里翁治疗有限公司 | 2023-09-12 | — | — | CN | claimed |
| EP-4233851-A1 | A SOLUBLE GUANYLAT CYCLASE ACTIVATOR FOR TREATING CHRONIC VASCULAR DYSFUNCTION | Charité - Universitätsmedizin Berlin (DE) | 2023-08-30 | — | — | EP | claimed |
| WO-2023148203-A1 | A SOLUBLE GUANYLAT CYCLASE ACTIVATOR FOR TREATING CHRONIC VASCULAR DYSFUNCTION | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2023-08-10 | — | — | WO | claimed |
| EP-4087469-A1 | DEVICES AND METHODS FOR TREATING CANCER AND CARDIAC WASTING | Nazzano Devices Limited (IE) | 2022-11-16 | — | — | EP | claimed |
| WO-2010081647-A2 | SGC STIMULATORS OF SGC ACTIVATORS IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-22 | — | — | WO | claimed |
| EP-2144605-A1 | sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS | Bayer HealthCare AG (DE) | 2010-01-20 | — | — | EP | claimed |
| WO-2009138165-A1 | SGC STIMULATORS, SGC ACTIVATORS AND COMBINATIONS THEREOF FOR THE TREATMENT OF HEARING IMPAIRMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-19 | — | — | WO | claimed |
| WO-2008138483-A1 | sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-20 | — | — | WO | claimed |
| US-20050181066-A1 | Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | US | claimed |
| US-20050059660-A1 | activators of soluble guanylate cyclase, and inhibitors of angiotensin converting enzyme such as benazepril; treatment of cardiovascular or metabolic disorders | PHARMACIA & UPJOHN COMPANY | 2005-03-17 | — | — | US | claimed |
| WO-2005011727-A1 | COMBINATION OF AN ACTIVATOR OF SOLUBLE GUANYLATE CYCLASE AND AN ACE-INHIBITOR FOR THE TREATMENT OF A CARDIOVASCULAR OR METABOLIC DISORDER | PFIZER LIMITED (GB) | 2005-02-10 | — | — | WO | claimed |
| EP-1501605-A1 | NOVEL USE OF GUANYLATE CYCLASE ACTIVATORS FOR THE TREATMENT OF RESPIRATORY INSUFFICIENCY | ALTANA Pharma AG (DE) | 2005-02-02 | — | — | EP | claimed |
| WO-2003090870-A1 | NOVEL USE OF GUANYLATE CYCLASE ACTIVATORS FOR THE TREATMENT OF RESPIRATORY INSUFFICIENCY | ALTANA PHARMA AG (DE) | 2003-11-06 | — | — | WO | claimed |
| WO-2001047494-A1 | METHOD FOR CO-GRINDING SUBSTANCES AND LACTOSE BY MEANS OF JET MILS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387391-A1 | A SOLUBLE GUANYLAT CYCLASE ACTIVATOR FOR TREATING CHRONIC VASCULAR DYSFUNCTION | GUCY1A1, PDE3B, PDE2A | ADORA3 1654/4885KCNH2 913/4885GUCY1A1 1/4885 |
| US-20250281485-A1 | DIAGNOSIS AND/OR TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION | NOX5, PDE5A, NOX1 | ADORA3 3645/4885KCNH2 1680/4885GUCY1A1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.